194 related articles for article (PubMed ID: 26542060)
1. The clinical benefits, ethics, and economics of stratified medicine and companion diagnostics.
Trusheim MR; Berndt ER
Drug Discov Today; 2015 Dec; 20(12):1439-50. PubMed ID: 26542060
[TBL] [Abstract][Full Text] [Related]
2. Precision medicine: what's all the fuss about?
Barker R
Scand J Clin Lab Invest Suppl; 2016; 245():S2-5. PubMed ID: 27542001
[TBL] [Abstract][Full Text] [Related]
3. The economic value of companion diagnostics and stratified medicines.
Blair ED; Stratton EK; Kaufmann M
Expert Rev Mol Diagn; 2012 Nov; 12(8):791-4. PubMed ID: 23249194
[No Abstract] [Full Text] [Related]
4. The Value of Companion Diagnostics: Overcoming Access Barriers to Transform Personalised Health Care into an Affordable Reality in Europe.
Wurcel V; Perche O; Lesteven D; Williams DA; Schäfer B; Hopley C; Jungwirth R; Postulka A; Pasmans R; Hermansson LL; Ott M; Glorioso V
Public Health Genomics; 2016; 19(3):137-43. PubMed ID: 27237134
[TBL] [Abstract][Full Text] [Related]
5. Do companion diagnostics make economic sense for drug developers?
Agarwal A
N Biotechnol; 2012 Sep; 29(6):695-708. PubMed ID: 22575210
[TBL] [Abstract][Full Text] [Related]
6. ENVIRONMENTAL SCAN ON PHARMACEUTICALS REQUIRING COMPANION DIAGNOSTICS.
Cowling T; Boucher M
Int J Technol Assess Health Care; 2016 Jan; 32(5):327-336. PubMed ID: 27955717
[TBL] [Abstract][Full Text] [Related]
7. Budget impact and cost-effectiveness: can we afford precision medicine in oncology?
Doble B
Scand J Clin Lab Invest Suppl; 2016; 245():S6-S11. PubMed ID: 27426412
[TBL] [Abstract][Full Text] [Related]
8. Challenges in the clinical implementation of precision medicine companion diagnostics.
Keeling P; Clark J; Finucane S
Expert Rev Mol Diagn; 2020 Jun; 20(6):593-599. PubMed ID: 32336167
[TBL] [Abstract][Full Text] [Related]
9. Clinical and economic challenges facing pharmacogenomics.
Cohen J; Wilson A; Manzolillo K
Pharmacogenomics J; 2013 Aug; 13(4):378-88. PubMed ID: 22231566
[TBL] [Abstract][Full Text] [Related]
10. Shedding Light on Reimbursement Policies of Companion Diagnostics in European Countries.
Govaerts L; Simoens S; Van Dyck W; Huys I
Value Health; 2020 May; 23(5):606-615. PubMed ID: 32389226
[TBL] [Abstract][Full Text] [Related]
11. Economic viability of Stratified Medicine concepts: An investor perspective on drivers and conditions that favour using Stratified Medicine approaches in a cost-contained healthcare environment.
Fugel HJ; Nuijten M; Postma M
N Biotechnol; 2016 Dec; 33(6):860-867. PubMed ID: 27664792
[TBL] [Abstract][Full Text] [Related]
12. Cost Implications of Value-Based Pricing for Companion Diagnostic Tests in Precision Medicine.
Zaric GS
Pharmacoeconomics; 2016 Jul; 34(7):635-44. PubMed ID: 26899833
[TBL] [Abstract][Full Text] [Related]
13. Best practices for companion diagnostic and therapeutic development: translating between the stakeholders.
Love D; Stratton E; Stocum M
N Biotechnol; 2012 Sep; 29(6):689-94. PubMed ID: 22743138
[TBL] [Abstract][Full Text] [Related]
14. Companion and complementary diagnostics for infectious diseases.
Dailey PJ; Elbeik T; Holodniy M
Expert Rev Mol Diagn; 2020 Jun; 20(6):619-636. PubMed ID: 32031431
[TBL] [Abstract][Full Text] [Related]
15. The impact of new trends in POCTs for companion diagnostics, non-invasive testing and molecular diagnostics.
Huckle D
Expert Rev Mol Diagn; 2015 Jun; 15(6):815-27. PubMed ID: 25990929
[TBL] [Abstract][Full Text] [Related]
16. The Health Technology Assessment of companion diagnostics: experience of NICE.
Byron SK; Crabb N; George E; Marlow M; Newland A
Clin Cancer Res; 2014 Mar; 20(6):1469-76. PubMed ID: 24634470
[TBL] [Abstract][Full Text] [Related]
17. The current and future state of companion diagnostics.
Agarwal A; Ressler D; Snyder G
Pharmgenomics Pers Med; 2015; 8():99-110. PubMed ID: 25897259
[TBL] [Abstract][Full Text] [Related]
18. The Regulation of Companion Diagnostics: A Global Perspective.
Ansari M
Ther Innov Regul Sci; 2013 Jul; 47(4):405-415. PubMed ID: 30235516
[TBL] [Abstract][Full Text] [Related]
19. An evaluation of regulatory and commercial barriers to stratified medicine development and adoption.
Meadows NA; Morrison A; Brindley DA; Schuh A; Barker RW
Pharmacogenomics J; 2015 Feb; 15(1):6-12. PubMed ID: 25287070
[TBL] [Abstract][Full Text] [Related]
20. Aligning the economic value of companion diagnostics and stratified medicines.
Blair ED; Stratton EK; Kaufmann M
J Pers Med; 2012 Nov; 2(4):257-66. PubMed ID: 25562363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]